Prothena | PRTA - Gross Profit On Sales


Prothena reported $51.08M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
ALKERMES USD 331.33M 7M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amgen USD 6.89B 415M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Exelixis USD 590.86M 18.68M Mar/2026
Immunic 0 0 Mar/2025
Incyte USD 1.17B 217.51M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
MacroGenics USD 11.24M 19.87M Mar/2026
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Prothena USD 51.08M 51.06M Mar/2026
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026